• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 6-K filed by Alterity Therapeutics Limited

    7/9/26 6:01:12 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ATHE alert in real time by email
    6-K 1 athe20260709_6k.htm FORM 6-K athe20260709_6k.htm

     

     

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 6-K

     

    REPORT OF FOREIGN PRIVATE ISSUER

    PURSUANT TO RULE 13a-16 OR 15d-163

    UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    For the month of July 2026

     

    Alterity Therapeutics Limited

    (Name of Registrant)

     

    Level 15, 500 Collins Street, Melbourne, Victoria 3000 Australia

    (Address of Principal Executive Office)

     

    Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

     

    Form 20-F ☒       Form 40-F ☐

     

    This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)

     

     

     
     

     

    ALTERITY THERAPEUTICS LIMITED

    (a development stage enterprise)

     

    The following exhibits are submitted:

     

    99.1

    Application for quotation of securities - ATH

     

    1

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

     

     

    Alterity Therapeutics Limited

         
     

    By:

    /s/ Julian Babarczy

       

    Julian Babarczy

       

    Chairman

     

    Date: July 9, 2026

     

     

    2
    Get the next $ATHE alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ATHE

    DatePrice TargetRatingAnalyst
    6/16/2026$10.00Buy
    Ladenburg Thalmann
    2/3/2025Speculative Buy → Hold
    The Benchmark Company
    12/12/2024$8.00Buy
    Maxim Group
    8/20/2021$4.00Speculative Buy
    Benchmark
    More analyst ratings

    $ATHE
    SEC Filings

    View All

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    7/21/26 6:02:42 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    7/21/26 6:01:01 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Alterity Therapeutics Limited

    6-K - ALTERITY THERAPEUTICS LTD (0001131343) (Filer)

    7/9/26 6:01:36 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026

    MELBOURNE, Australia and SAN FRANCISCO, July 21, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that David Stamler, M.D., Chief Executive Officer, will participate in the BTIG Biotechnology Conference 2026 taking place virtually 28-29 July 2026. At the conference, Dr. Stamler will host 1-on-1 meetings with investors in the United States.  About Alterity Therapeutics Limited Alterity Therapeutics is a clinical stage biotechnology company dedicated to creating an alternate future for people living with neurodeg

    7/21/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Receives FDA End-of-Phase 2 Meeting Minutes Confirming Registrational Pathway for ATH434 in Multiple System Atrophy

    – Official FDA minutes confirm the previously announced End-of-Phase 2 meeting outcomes and provide additional detail on the planned Phase 3 protocol — – FDA agreed that a single pivotal Phase 3 trial plus confirmatory evidence could support an approval of ATH434 for the treatment of MSA – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, July 07, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that it has received the official meeting minutes fr

    7/7/26 7:05:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Achieves Alignment with U.S. FDA on Pivotal Phase 3 Program for ATH434 in Multiple System Atrophy

    – Successful End-of-Phase 2 meeting with FDA agreeing on key elements of the proposed Phase 3 design, including study population, dosing regimen, and treatment duration – – FDA agrees on UMSARS Part I as primary endpoint after ATH434 demonstrated 48% slowing of disease progression versus placebo in Phase 2 study – – FDA agrees with 50mg dose level which achieved clinically and statistically significant efficacy in Phase 2 study – – Pivotal Phase 3 trial activities on track to initiate by year-end 2026 – MELBOURNE, Australia and SAN FRANCISCO, June 09, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, trading under the ASX code ATHDA until 12 June, NASDAQ:ATHE) ("Alterity" or

    6/9/26 7:05:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Babarczy Julian Michael

    4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)

    6/23/26 7:57:44 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Gozlan Lawrence Bernard

    4 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)

    6/23/26 7:38:00 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Cunningham Ann Michelle

    3 - ALTERITY THERAPEUTICS LTD (0001131343) (Issuer)

    4/29/26 8:05:07 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ladenburg Thalmann resumed coverage on Alterity Therapeutics with a new price target

    Ladenburg Thalmann resumed coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $10.00

    6/16/26 8:05:58 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics downgraded by The Benchmark Company

    The Benchmark Company downgraded Alterity Therapeutics from Speculative Buy to Hold

    2/3/25 7:02:17 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Maxim Group initiated coverage on Alterity Therapeutics with a new price target

    Maxim Group initiated coverage of Alterity Therapeutics with a rating of Buy and set a new price target of $8.00

    12/12/24 8:39:51 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Leadership Updates

    Live Leadership Updates

    View All

    Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update

    Highlights Aligned with the FDA in two Positive Type C meetings supporting key elements of the planned Phase 3 program for ATH434 in MSAAdvancing ATH434 toward pivotal Phase 3 program; on track for End-of-Phase 2 FDA meeting mid-year 2026Late breaking platform presentation at American Academy of Neurology annual meeting demonstrated consistent evidence of efficacy and reinforces ATH434's clinical profileStrengthened clinical leadership with appointment of Dr. Daniel Claassen as Chief Medical AdvisorEnhanced Board of Directors with appointment of Ms. Ann Cunningham, bringing extensive global commercial and neurodegenerative disease expertiseHosted a virtual KOL event featuring leading expe

    4/30/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors

    MELBOURNE, Australia and SAN FRANCISCO, April 17, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the appointment of Ms Ann Cunningham to its Board of Directors as an independent Non-Executive Director, effective 17th April 2026. Ms Cunningham's appointment further strengthens Alterity's Board composition, adding significant global commercial and strategic expertise as the Company transitions toward late-stage development in Multiple System Atrophy (MSA). Ms Cunningham brings more than 25 years of global pharmac

    4/17/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor

    MELBOURNE, Australia and SAN FRANCISCO, March 04, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that Daniel O. Claassen, M.D., M.S., was appointed Chief Medical Advisor and will begin his role in March 2026. As a tenured professor, Dr. Claassen will also retain his academic appointment at Vanderbilt University Medical Center. Dr. Claassen is a board-certified neurologist and internationally recognized expert in neurodegenerative diseases, with more than two decades of clinical and translational research in mov

    3/4/26 7:25:00 AM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ATHE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    10/31/22 5:29:16 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    8/26/22 5:16:24 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D/A filed by Alterity Therapeutics Limited (Amendment)

    SC 13D/A - ALTERITY THERAPEUTICS LTD (0001131343) (Subject)

    8/1/22 5:21:53 PM ET
    $ATHE
    Biotechnology: Pharmaceutical Preparations
    Health Care